Drug companies and pharmacies have reached a $17.3 billion settlement over the o...
The FDA issued a warning to device maker iRhythm for marketing its product for “...
"It would be hard for me to convince my leadership to take that leap again so so...
The grim reality is there will never be enough trained therapists to meet the de...
Join Frank David and Ken Getz to discuss the practical factors that add risk to ...
"The patient community, all payers, all regulatory agencies, they all welcome mu...
The FDA is convening a meeting of outside experts today to consider full approva...
Updated results highlighted the ongoing benefits of a CRISPR-based medicine for ...
Follow our live blog of an FDA advisory panel's hearing on Leqembi, Eisai and Bi...
About 80% of large companies self-insure, meaning that their employee health pla...
The experts who scrutinized the manuscript for the journal before it was publish...
The fast track designation enables increased communication with the FDA througho...
KT430 delivers a functional copy of the MTM1 gene through a new MyoAAV capsid to...
The Prescription Cost Analysis also highlighted that the drug with the largest i...
The committee overwhelmingly supported nirsevimab’s risk-benefit profile in both...
VEVYE is a topical anti-inflammatory and immunomodulating ophthalmic drug solution.
